No Data
No Data
Exact Sciences Schedules Second Quarter 2024 Earnings Call
Exact Sciences Corp. (NASDAQ:EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S.
People Are Feeling Stuck in Their Jobs. Bosses Are Starting to Worry. -- WSJ
By Chip Cutter You are likely not getting a big promotion this year. So how about a job swap? Many workers say they are considering that question as they feel stuck in their roles. With the white-co
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Price Target Cut to $72.00/Share From $80.00 by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Is Maintained at Outperform by Evercore ISI Group
Exact Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/02/2024 67.42% Evercore ISI Group $80 → $72 Maintains Outperform 06/27/2024 62.77% BTIG $80 → $70 Maint
Evercore Maintains Exact Sciences(EXAS.US) With Buy Rating, Cuts Target Price to $72
Evercore analyst Vijay Kumar maintains $Exact Sciences(EXAS.US)$ with a buy rating, and adjusts the target price from $90 to $72.According to TipRanks data, the analyst has a success rate of 47.4% and
No Data
Baboompiak : yup holding onto 100 shares at 57.5